Open Access iconOpen Access

ARTICLE

crossmark

Deoxynortryptoquivaline: A unique antiprostate cancer agent

YOHKO YAMAZAKI1,*, MANABU KAWADA2, ISAO MOMOSE1

1 Institute of Microbial Chemistry (BIKAKEN), Numazu Branch, Microbial Chemistry Research Foundation, Numazu, 410-0301, Japan
2 Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Shinagawa-ku, 141-0021, Japan

* Corresponding Author: YOHKO YAMAZAKI. Email: email

(This article belongs to the Special Issue: Approach from Chemical Biology for Cancer Research)

Oncology Research 2023, 31(6), 845-853. https://doi.org/10.32604/or.2023.030266

Abstract

The androgen receptor (AR) is a critical target in all the clinical stages of prostate cancer. To identify a new AR inhibitor, we constructed a new screening system using the androgen-dependent growth of prostate cancer cell lines as a screening indicator. We screened 50,000 culture broths of microorganisms using this screening system and found that the fermentation broth produced by a fungus inhibited androgen-dependent growth of human prostate cancer LNCaP cells without cytotoxicity. Purification of this culture medium was performed, and this resulted in deoxynortryptoquivaline (DNT) being identified as a novel inhibitor of AR function. DNT showed potent inhibition of androgen-dependent growth of human prostate cancer LNCaP cells. The AR competitor assay was performed, and DNT did not act as an AR antagonist. However, DNT inhibited AR-dependent transcriptional activity and AR nuclear translocation, it suggested that the suppression of AR function leads to inhibition activity against androgen-dependent growth.

Graphic Abstract

Deoxynortryptoquivaline: A unique antiprostate cancer agent

Keywords


Cite This Article

APA Style
YAMAZAKI, Y., KAWADA, M., MOMOSE, I. (2023). Deoxynortryptoquivaline: A unique antiprostate cancer agent. Oncology Research, 31(6), 845-853. https://doi.org/10.32604/or.2023.030266
Vancouver Style
YAMAZAKI Y, KAWADA M, MOMOSE I. Deoxynortryptoquivaline: A unique antiprostate cancer agent. Oncol Res. 2023;31(6):845-853 https://doi.org/10.32604/or.2023.030266
IEEE Style
Y. YAMAZAKI, M. KAWADA, and I. MOMOSE "Deoxynortryptoquivaline: A unique antiprostate cancer agent," Oncol. Res., vol. 31, no. 6, pp. 845-853. 2023. https://doi.org/10.32604/or.2023.030266



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1327

    View

  • 307

    Download

  • 0

    Like

Share Link